Department of Toxicology, Center for Pharmaceutical Research (CePhar), Vrije Universiteit Brussel (VUB), Belgium.
Toxicology. 2013 Oct 4;312:158-65. doi: 10.1016/j.tox.2013.08.011. Epub 2013 Aug 23.
Adverse outcome pathways (AOPs) are novel tools in toxicology and human risk assessment with broad potential. AOPs are designed to provide a clear-cut mechanistic representation of critical toxicological effects that span over different layers of biological organization. AOPs share a common structure consisting of a molecular initiating event, a series of intermediate steps and key events, and an adverse outcome. Development of AOPs ideally complies with OECD guidelines. This also holds true for AOP evaluation, which includes consideration of the Bradford Hill criteria for weight-of-evidence assessment and meeting a set of key questions defined by the OECD. Elaborate AOP frameworks have yet been proposed for chemical-induced skin sensitization, cholestasis, liver fibrosis and liver steatosis. These newly postulated AOPs can serve a number of ubiquitous purposes, including the establishment of (quantitative) structure-activity relationships, the development of novel in vitro toxicity screening tests and the elaboration of prioritization strategies.
不良结局途径(AOP)是毒理学和人类风险评估中具有广泛潜力的新型工具。AOP 旨在提供跨越不同生物组织层次的关键毒理学效应的清晰机制表示。AOP 具有共同的结构,包括分子起始事件、一系列中间步骤和关键事件以及不良结局。AOP 的开发理想情况下符合 OECD 指南。AOP 评估也是如此,其中包括考虑用于证据权重评估的 Bradford Hill 标准,并满足 OECD 定义的一组关键问题。已经为化学诱导的皮肤致敏、胆汁淤积、肝纤维化和肝脂肪变性提出了详细的 AOP 框架。这些新提出的 AOP 可以用于许多普遍的目的,包括建立(定量)结构-活性关系、开发新型体外毒性筛选测试和制定优先级策略。